

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
PARKER ET AL.

Examiner: L. R. Helms

Art Unit: 1642

Serial No.: **09/719,758**

Filed: January 4, 2002

Title: **MONOCLONAL ANTIBODIES
DIRECTED AGAINST THE G3BP
PROTEIN AND USES**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
First Class Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C.
20231, on

10/16/2003
Date of Deposit
Signature James Pierce, Sr.

STATEMENT IN SUPPORT OF FILING AND SUBMISSION OF SEQUENCE LISTING

Commissioner for Patents
Mail Stop PCT
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In connection with the Sequence Listing filed concurrently herewith, the undersigned states that

1. The submission does not contain new matter.
2. The content of the attached paper copy and the attached computer readable copy of the Sequence Listing are the same.

//

//

//

//

//


//

//

//

3. I declare under the laws of the United States of America that all statements of fact set forth above are true, and recognize that willfully false statements may jeopardize the validity of any patent that issues from this application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. B. German', written over a horizontal line.

Joel B. German, Reg. No. 48,676
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3444
Telefax (908) 231-2626
Aventis Docket No. ST98017 US